Associations Do Not Equal Causation: Clinical Relevance of Statistical Associations of Phosphodiesterase Type 5 Inhibitors with Prostate Cancer Progression and Melanoma

Eur Urol. 2015 Nov;68(5):754-5. doi: 10.1016/j.eururo.2015.07.023. Epub 2015 Jul 31.

Authors

Stacy Loeb¹, Thorsten Schlomm², Pär Stattin³

Affiliations

¹ Department of Urology, Population Health, and Laura & Isaac Perlmutter Cancer Center, New York University, New York, NY, USA. Electronic address: stacyloeb@gmail.com.
² Martini-Clinic Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
³ Department of Surgery and Perioperative Sciences, Urology and Andrology, Umeå University Hospital, Umeå, Sweden.

PMID: 26238432
DOI: 10.1016/j.eururo.2015.07.023

No abstract available

Publication types

Editorial
Comment

MeSH terms

Erectile Dysfunction / drug therapy*
Humans
Kallikreins / blood*
Male
Neoplasm Recurrence, Local / epidemiology*
Phosphodiesterase 5 Inhibitors / therapeutic use*
Postoperative Complications / drug therapy*
Prostate-Specific Antigen / blood*
Prostatectomy*
Prostatic Neoplasms / surgery*

Substances

Phosphodiesterase 5 Inhibitors
Kallikreins
kallikrein-related peptidase 3, human
Prostate-Specific Antigen